Gilead-part­nered Vi­en­na-based im­munother­a­py com­pa­ny Hookipa makes Nas­daq de­but with down­sized $84M IPO

Gilead-part­nered im­munother­a­py de­vel­op­er Hookipa has been work­ing on tech­nol­o­gy us­ing are­navirus­es — a fam­i­ly of virus­es typ­i­cal­ly host­ed by ro­dents — to tur­bocharge the hu­man im­mune sys­tem to fight in­fec­tious dis­eases and can­cers. The Vi­en­na-based com­pa­ny on Wednes­day priced a down­sized IPO at the low end of its range at $14, rais­ing gross pro­ceeds of $84 mil­lion.

Co-found­ed by Rolf Zinker­nagel — who was award­ed the 1996 No­bel Prize in Phys­i­ol­o­gy or Med­i­cine for his are­navirus-based work — the com­pa­ny will be­gin trad­ing un­der the tick­er sym­bol “HOOK” on Thurs­day.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER